Education
About Us
Working with TipRanks
Follow Us
Novonesis (NVZMY)
OTHER OTC:NVZMY
Earnings Data
Report Date
Aug 21, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
0.75Last Year’s EPS
0.69Same Quarter Last Year
Based on 0 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 08, 2025
|% Change Since: 14.85%
|Next Earnings Date:Aug 21, 2025
Earnings Call Sentiment|Positive
The earnings call reflects a strong start to 2025 with robust organic sales growth and profitability improvements, despite challenges from market exits and currency headwinds. The company's diversified portfolio and strategic acquisitions position it well for future growth.Company Guidance
During the Novonesis conference call for the first quarter of 2025, the company reported an 11% organic sales growth, with a 10% growth in volume and a 1% increase in pricing. Emerging markets exhibited a robust 15% growth, while developed markets grew by 9%. The company launched six new biosolutions, contributing to the sales growth. The adjusted EBITDA margin for the quarter was 38.3%, a 3.1 percentage point increase from the previous year. Novonesis maintained its full-year guidance, expecting 5% to 8% organic sales growth, accounting for a 1 percentage point negative impact from exiting Russia and Belarus. The adjusted EBITDA margin is anticipated to remain between 37% and 38%, despite currency headwinds. The company's diversified portfolio, strong customer focus, and innovation capabilities were highlighted as key drivers for sustained growth and margin expansion in 2025.Strong Organic Sales Growth
Novonesis achieved an 11% organic sales growth in Q1 2025, with 15% growth in emerging markets and 9% in developed markets.
Adjusted EBITDA Margin Improvement
The adjusted EBITDA margin increased to 38.3%, a 3.1% rise compared to the previous year, driven by strong sales growth and cost synergies.
Successful Product Launches
Six new biosolutions were launched, primarily in household care and food, with expectations for further launches in the coming quarters.
Strategic Acquisition
The acquisition of dsm-firmenich’s part of the Feed Enzyme Alliance is expected to close in Q2 2025, enhancing Novonesis's position in animal biosolutions.
Strong Performance in Human Health
Human health delivered 13% organic sales growth, driven by dietary supplements and advanced protein solutions in North America and Europe.
NVZMY Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
NVZMY Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 08, 2025 | $64.86 | $67.16 | +3.55% |
Feb 26, 2025 | $56.66 | $59.93 | +5.77% |
Nov 07, 2024 | $58.36 | $61.08 | +4.66% |
Aug 27, 2024 | $66.93 | $67.52 | +0.88% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Novonesis (NVZMY) report earnings?
Novonesis (NVZMY) is schdueled to report earning on Aug 21, 2025, TBA Not Confirmed.
What is Novonesis (NVZMY) earnings time?
Novonesis (NVZMY) earnings time is at Aug 21, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is NVZMY EPS forecast?
NVZMY EPS forecast for the fiscal quarter 2025 (Q2) is 0.75.